Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Is Depression During Pregnancy on the Rise?Know the Signs of Postpartum DepressionAre Your Meds Making You Depressed?Depression, Money Woes Higher in Heart Patients With Job LossSnubbed on Social Media? Your Depression Risk May RiseNever Ignore DepressionStudy Affirms What Many Know: Antidepressants May Lead to Weight GainECT Effective for Treatment-Resistant DepressionRates of Major Depression Up Among U.S. Insured, Esp. YouthResistance Exercise May Reduce Depressive Symptoms in AdultsDepression Striking More Young People Than EverDepression May Dampen MemoryCould Mom-to-Be's Antidepressants Have an Upside for Baby's Brain?Exercise Your Blues AwayGrip Strength Indicative of Cognition in Major DepressionKetamine Nasal Spray Shows Promise Against Depression, SuicideTelltale Clues That Your Child Is DepressedPrenatal Exposure to SSRI Tied to Fetal Brain DevelopmentDepressive Symptoms Tied to Diabetes Self-ManagementAbandoning Your Workouts May Bring on the BluesMany Grad Students Struggle With Anxiety, DepressionRelapse in Major Depression Linked to Brain Cortical ChangesIL-6 Levels Predict Response to ECT in Depressive Disorder1 in 20 Younger Women Suffers Major DepressionHeart-Healthy 'DASH' Diet May Also Help Lower Depression RiskGuidelines Updated for Managing and ID'ing Adolescent Depression21 Reviewed Antidepressants Top Placebo for Major DepressionAntidepressants Do Work, Some Better Than Others: StudyTreatment Initiation for Depression Low in Primary CareDuring 2013 to 2016, 8.1 Percent of U.S. Adults Had DepressionDepression Common in U.S., Women Hit HardestNo Proof At-Home 'Cranial Stimulation' Eases DepressionAcne Linked to Increased Risk of Major Depressive DisorderMany With Depression Delay, Avoid TreatmentPostnatal Depression Tied to Child Behavioral ProblemsTalk Therapy May Be Worth It for Teen DepressionCognitive Behavioral Therapy Cost-Effective in Depressed TeensWomen Seem More Prone to Winter BluesTransdermal Estradiol May Help Prevent Depressive SymptomsHormone Therapy May Ease Depression Linked to MenopauseEsketamine Safe, Effective for Treatment-Resistant DepressionDermatologists Often Undervalue Depression, Anxiety in PatientsFeeling Sad? Here's How to Beat the Holiday BluesImpaired White Matter Integrity for Depression in Parkinson'sHealth Tip: Fight Seasonal Affective DisorderNetwork Density Not Linked to Response in Teen DepressionSimple ECG May Help Distinguish MDD From Bipolar DepressionTreatment Trajectories Vary for Children With DepressionIf Dad Has Depression, Kids Might Develop It, TooPsychedelic Amazonian Drug Might Ease Symptoms of Depression, Alcoholism
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

Prenatal Exposure to SSRI Tied to Fetal Brain Development


HealthDay News
Updated: Apr 9th 2018

new article illustration

MONDAY, April 9, 2018 (HealthDay News) -- Prenatal exposure to a selective serotonin reuptake inhibitor (SSRI) is associated with fetal brain development, according to a study published online April 9 in JAMA Pediatrics.

Claudia Lugo-Candelas, Ph.D., from the Columbia University Medical Center in New York City, and colleagues examined the correlations between prenatal SSRI exposure and brain development in a cohort of 98 infants. Of these, 16 had in utero SSRI exposure, 21 had in utero untreated maternal depression exposure, and 61 were healthy controls. Brain development was assessed using structural and diffusion magnetic resonance imaging (MRI).

The researchers found that infants underwent MRI at a mean age of 3.43 weeks. Compared with both healthy controls and infants exposed to untreated maternal depression, significant gray matter volume expansion was seen in the right amygdala and right insula in SSRI-exposed infants in voxel-based morphometry. The SSRI group showed a significant increase in connectivity between the right amygdala and the right insula in connectome-level analysis of white matter structural connectivity, with a large effect size relative to healthy controls and infants exposed to untreated depression.

"Our findings suggest that prenatal SSRI exposure has an association with fetal brain development, particularly in brain regions critical to emotional processing," the authors write. "The study highlights the need for further research on the potential long-term behavioral and psychological outcomes of these neurodevelopmental changes."

One author disclosed financial ties to the medical device and pharmaceutical industries.

Abstract/Full Text